Navigation Links
Implantable slimming aid
Date:11/26/2013

Humankind has a weight problem and not only in the industrialised nations, either: the growing prosperity in many Asian or Latin American countries goes hand in hand with a way of life that quite literally has hefty consequences. Ac-cording to the WHO, over half the population in many industrialised nations is overweight, one in three people extremely so. Not only is high-calorie and fatty food a lifetime on the hips, backside and stomach; it also leaves traces in the blood, where various fats ingested via food circulate. Increased blood-fat values are also regarded as a risk factor for heart attacks and strokes.

Genetic regulatory circuit monitors blood fat

The research group headed by ETH-Zurich professor Martin Fussenegger from the Department of Biosystems Science and Engineering in Basel has now de-veloped an early warning system and treatment: an implantable genetic circuit mainly composed of human gene components. On the one hand, it constantly monitors the circulating fat levels in the blood. On the other hand, it has a feed-back function and forms a messenger substance in response to excessively high blood-fat levels that conveys a sense of satiety to the body.

In order to construct this highly complex regulatory circuit, the biotechnologists skilfully combined different genes that produce particular proteins and reaction steps. They implanted the construct in human cells, which they then inserted into tiny capsules.

The researchers studied obese mice that had been fed fatty food. After the cap-sules with the gene regulatory circuit had been implanted in the animals and intervened due to the excessive levels, the obese mice stopped eating and their bodyweight dropped noticeably as a result. As the blood-fat levels also returned to normal, the regulatory circuit stopped producing the satiety signal.

"The mice lost weight although we kept giving them as much high-calorie food as they could eat," stresses Fussenegger. The animals ate less because the implant signalised a feeling of satiety to them. Mice that received normal animal feed with a five-per-cent fat content did not lose any weight or reduce their intake of food, says the biotechnologist.

Sensor for different dietary fats

One major advantage of the new synthetic regulatory circuit is the fact that it is not only able to measure one sort of fat, but rather several saturated and un-saturated animal and vegetable fats that are ingested with food at once. How-ever, this development cannot simply be transferred to humans. It will take many years to develop a suitable product. Nonetheless, Fussenegger can certainly envisage that one day obese people with a body mass index of way over thirty could have such a gene network implanted to help them lose weight. Fussenegger sees the development as a possible alternative to surgical inter-ventions such as liposuction or gastric bands. "The advantage of our implant would be that it can be used without such invasive interventions." Another merit: instead of intervening in the progression of a disease that is difficult to regulate, it has a preventive effect and exploits the natural human satiety mechanism.

This gene network is one of the most complex that Fussenegger and his team have constructed to date and was made possible thanks to the biotechnologist's years of experience in the field. It is not the first time he and his team have suc-ceeded in constructing such a complex feedback regulatory circuit: a number of years ago, they produced an implant that can also be used to combat gout via a feedback regulatory circuit.


'/>"/>

Contact: Martin Fussenegger
martin.fussenegger@bsse.ethz.ch
41-613-873-160
ETH Zurich
Source:Eurekalert  

Related biology technology :

1. Allegheny General Hospital Cardiovascular Team Introduces New MRI Capability for Patients with Pacemakers, Implantable Defibrillators
2. Global Implantable Drug Delivery Devices Market - New Industry Research Report Published by Transparency Market Research
3. U.S. Implantable Medical Devices Market is Expected to Reach USD 73.9 Billion by 2018: Transparency Market Research
4. First successful human results achieved: Implantable wireless microchip drug delivery device
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Implantable slimming aid
(Date:3/22/2017)... ... March 21, 2017 , ... Functional near-infrared spectroscopy (fNIRS), an optical imaging tool ... way to track the brain’s response to acute pain in adults and infants. , ... ,” published today in the journal Neurophotonics , by SPIE, the international ...
(Date:3/22/2017)... 22, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced ... will present at the 5th Annual Cancer BioPartnering ... platform to present to and meet with thought ... biotech companies as well as institutional investors. This ...
(Date:3/20/2017)... CA (PRWEB) , ... March 20, 2017 , ... ... therapies for gastrointestinal (GI) disorders, today announced that it has entered into an ... for therapies in inflammatory bowel disease including Necrotizing Enterocolitis (rare orphan disease) as ...
(Date:3/20/2017)... Foreside, Maine (PRWEB) , ... March 20, 2017 ... ... announce its VALIDATE® HEPARIN calibration verification / linearity test kit has received US ... systems. The VALIDATE® HEPARIN kit evaluates Heparin Anti-Xa activity in a human ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has ... World Lung Imaging Workshop at the University of Pennsylvania. ... invited to deliver the latest data to world leaders ... event brings together leaders at the forefront of the ... lung imaging. "The quality of the ...
(Date:3/6/2017)... Calif. , March 6, 2017 ... and sales technology, today announced Predictive Sales Coach ... for infusing actionable sales intelligence into Salesforce. This ... automatically enable their sales organizations with deep knowledge ... that allow for intelligent engagement. Predictive Sales Coach ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
Breaking Biology News(10 mins):